Literature DB >> 7854252

Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis.

W L Beatty1, R P Morrison, G I Byrne.   

Abstract

Chlamydiae are medically important bacteria responsible for a wide range of human infections and diseases. Repeated episodes of infection promote chronic inflammation associated with detrimental immune system-mediated pathologic changes. However, the true nature of chlamydial pathogenesis may encompass repeated infection superimposed upon persistent infection, which would allow for heightened immune reactivity. During the course of chlamydial infection, numerous host elaborated factors with inhibitory or modifying effects may cause alterations in the chlamydia-host cell relationship such that the organism is maintained in a nonproductive stage of growth. Abnormal or persistent chlamydiae have been recognized under a variety of cell culture systems. The numerous factors associated with altered growth suggest an innate flexibility in the developmental cycle of chlamydiae. This review evaluates in vitro studies of chlamydial persistence and correlates these model systems to features of natural chlamydial disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7854252      PMCID: PMC372987          DOI: 10.1128/mr.58.4.686-699.1994

Source DB:  PubMed          Journal:  Microbiol Rev        ISSN: 0146-0749


  113 in total

1.  Chlamydia trachomatis-host cell interactions: role of the chlamydial major outer membrane protein as an adhesin.

Authors:  H Su; N G Watkins; Y X Zhang; H D Caldwell
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

2.  Developmental regulation of tandem promoters for the major outer membrane protein gene of Chlamydia trachomatis.

Authors:  R S Stephens; E A Wagar; U Edman
Journal:  J Bacteriol       Date:  1988-02       Impact factor: 3.490

3.  The carrier state: Chlamydia trachomatis.

Authors:  J D Oriel
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

4.  Endocervical chlamydial deoxyribonucleic acid in infertile women.

Authors:  Y K Soong; S M Kao; C J Lee; P S Lee; C C Pao
Journal:  Fertil Steril       Date:  1990-11       Impact factor: 7.329

5.  Identification of an early-stage gene of Chlamydia psittaci 6BC.

Authors:  D G Wichlan; T P Hatch
Journal:  J Bacteriol       Date:  1993-05       Impact factor: 3.490

6.  Cyclic AMP inhibits protein synthesis in Chlamydia trachomatis at a transcriptional level.

Authors:  R Kaul; S Tao; W M Wenman
Journal:  Biochim Biophys Acta       Date:  1990-06-12

7.  A comparison of the fallopian tube's response to overt and silent salpingitis.

Authors:  D L Patton; D E Moore; L R Spadoni; M R Soules; S A Halbert; S P Wang
Journal:  Obstet Gynecol       Date:  1989-04       Impact factor: 7.661

8.  Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro.

Authors:  W L Beatty; G I Byrne; R P Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

9.  Diagnosis and prevalence of persistent chlamydia infection in infertile women: tissue culture, direct antigen detection, and serology.

Authors:  H Thejls; J Gnarpe; O Lundkvist; G Heimer; G Larsson; A Victor
Journal:  Fertil Steril       Date:  1991-02       Impact factor: 7.329

10.  INHIBITION OF THE GROWTH OF AGENTS OF THE PSITTACOSIS GROUP BY D-CYCLOSERINE AND ITS SPECIFIC REVERSAL BY D-ALANINE.

Authors:  J W MOULDER; D L NOVOSEL; J E OFFICER
Journal:  J Bacteriol       Date:  1963-03       Impact factor: 3.490

View more
  193 in total

1.  cDNA array analysis of altered gene expression in human endothelial cells in response to Chlamydia pneumoniae infection.

Authors:  B K Coombes; J B Mahony
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 2.  Diagnosis of viral and chlamydial keratoconjunctivitis: which laboratory test?

Authors:  E M Elnifro; R J Cooper; P E Klapper; A S Bailey; A B Tullo
Journal:  Br J Ophthalmol       Date:  1999-05       Impact factor: 4.638

3.  Inhibition of Chlamydia pneumoniae replication in human aortic smooth muscle cells by gamma interferon-induced indoleamine 2, 3-dioxygenase activity.

Authors:  L G Pantoja; R D Miller; J A Ramirez; R E Molestina; J T Summersgill
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

4.  Analytical sensitivity, reproducibility of results, and clinical performance of five PCR assays for detecting Chlamydia pneumoniae DNA in peripheral blood mononuclear cells.

Authors:  J B Mahony; S Chong; B K Coombes; M Smieja; A Petrich
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

5.  Characterization of Chlamydia pneumoniae persistence in HEp-2 cells treated with gamma interferon.

Authors:  L G Pantoja; R D Miller; J A Ramirez; R E Molestina; J T Summersgill
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

6.  Chlamydia pneumoniae secretion of a protease-like activity factor for degrading host cell transcription factors required for [correction of factors is required for] major histocompatibility complex antigen expression.

Authors:  Peiyi Fan; Feng Dong; Yanqing Huang; Guangming Zhong
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

7.  Ultrastructural study of Chlamydia pneumoniae in a continuous-infection model.

Authors:  A Kutlin; C Flegg; D Stenzel; T Reznik; P M Roblin; S Mathews; P Timms; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

Review 8.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 9.  Immunological basis of Chlamydia induced reactive arthritis.

Authors:  J S Gaston
Journal:  Sex Transm Infect       Date:  2000-06       Impact factor: 3.519

10.  Temporal expression of type III secretion genes of Chlamydia pneumoniae.

Authors:  Anatoly Slepenkin; Vladimir Motin; Luis M de la Maza; Ellena M Peterson
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.